Detalhe da pesquisa
1.
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop).
Eur J Neurol
; 31(6): e16250, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38549186
2.
Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis.
Ann Neurol
; 91(4): 483-495, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35150168
3.
Comparing face-to-face and videoconference assessment of the Brief Repeatable Battery of Neuropsychological Tests in people with multiple sclerosis.
Mult Scler
; 29(10): 1337-1339, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37602442
4.
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
Brain
; 145(8): 2796-2805, 2022 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35325059
5.
Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective.
Neurol Sci
; 44(1): 45-58, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36114980
6.
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 2022 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36180219
7.
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy.
Mult Scler
; 28(1): 93-101, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33855897
8.
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.
Mult Scler
; 28(14): 2243-2252, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35971322
9.
A real-world study of alemtuzumab in a cohort of Italian patients.
Eur J Neurol
; 29(1): 257-266, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34558755
10.
Therapeutic Plasmapheresis: a revision of literature.
Kidney Blood Press Res
; 2022 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36481657
11.
Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case-control study.
Neurol Sci
; 43(4): 2601-2609, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34561786
12.
Disability assessment using Google Maps.
Neurol Sci
; 43(2): 1007-1014, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34142263
13.
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study.
Neurol Sci
; 43(11): 6415-6423, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35781765
14.
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
Mult Scler
; 27(3): 430-438, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33210986
15.
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
Brain
; 143(10): 3013-3024, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32935843
16.
Clinical and Genetic Heterogeneity in a Large Family with Pseudoxanthoma Elasticum: MTHFR and SERPINE1 Variants as Possible Disease Modifiers in Developing Ischemic Stroke.
J Stroke Cerebrovasc Dis
; 30(6): 105744, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33813081
17.
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study.
J Neurol Neurosurg Psychiatry
; 91(9): 914-920, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32661083
18.
Prognostic indicators in pediatric clinically isolated syndrome.
Ann Neurol
; 81(5): 729-739, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28439957
19.
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests.
Mult Scler
; 23(9): 1289-1296, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27811338
20.
Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon ß-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
BMC Neurol
; 17(1): 156, 2017 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28793876